Effects of MLN518 on WBC recovery from cyclophosphamide-induced myelosuppression. (A) Balb/c mice were treated with 180 mg/kg MLN518 twice daily (▪) or carrier (□) by oral gavage for 21 days. Cyclophosphamide (200 mg/kg) was injected intraperitoneally on day 3. Significant differences were observed on days 11, 17, and 21 (P < .05). (B) Three-part differential count for lymphocytes, monocytes, and granulocytes for MLN518 treatment group (solid symbols) and the carrier group (open symbols). Data represent the mean ± standard deviation.